Mer­ck’s Keytru­da fails more prostate and lung can­cer PhI­II tri­als

Mer­ck’s can­cer drug be­he­moth, the an­ti-PD1 Keytru­da, has failed two more Phase III tri­als in the hard-to-treat prostate can­cer set­ting and in a cer­tain lung …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.